clinical trial · NCT07184385
A Study of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Post-COVID Condition
StemCyte, Inc.·phase3·not yet recruiting·n = 60
Long COVIDPost-COVID-19 ConditionPost-COVID SyndromePost-COVID ConditionREGENECYTEPlacebo
brief summary
REGENECYTE (HPC, Cord Blood) for treatment in patients with post-COVID.
started
Mar 31, 2026
primary completion
Jun 30, 2027
completion
Sep 30, 2027
last updated
Sep 23, 2025
detailed description
This is a two-arm, multi-center, double-blind, randomized, placebo-controlled phase III study. A total of 60 subjects with post-COVID will be enrolled.
official title
A Multicenter, Double-blind, Randomized, Placebo-controlled, Two-arm Phase III Study to Assess the Efficacy of Human Umbilical Cord Blood (REGENECYTE) Infusion in Reducing Fatigue in Post-COVID Condition
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol